Anti-tumor immunostimulatory effect of heat-killed tumor cells

AS a part of our ongoing search for a safe and efficient anti-tumor vaccine, we attempted to determine whether the molecular nature of certain tumor antigens would influence immune responses against tumor cells. As compared with freeze-thawed or formaldehyde-fixed tumor antigens, heat-denatured tumo...

Full description

Saved in:
Bibliographic Details
Published inExperimental & molecular medicine Vol. 40; no. 1; pp. 130 - 144
Main Authors Yoon, Taek Joon, Kim, Ji Yeon, Kim, Hyojeong, Hong, Changwan, Lee, Hyunji, Lee, Chang-Kwon, Lee, Kwang Ho, Hong, Seokmann, Park, Se-Ho
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 01.02.2008
Springer Nature B.V
Korean Society of Medical Biochemistry and Molecular Biology
생화학분자생물학회
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:AS a part of our ongoing search for a safe and efficient anti-tumor vaccine, we attempted to determine whether the molecular nature of certain tumor antigens would influence immune responses against tumor cells. As compared with freeze-thawed or formaldehyde-fixed tumor antigens, heat-denatured tumor antigens elicited profound anti-tumor immune responses and greatly inhibited the growth of live tumor cells. The heat-denatured tumor antigens induced a substantial increase in the anti-tumor CTL response in the absence of any adjuvant material. This response appears to be initiated by strong activation of the antigen-presenting cells, which may recognize heat-denatured protein antigens. Upon recognition of the heat-denatured tumor antigens, macrophages and dendritic cells were found to acutely upregulate the expression of co-stimulatory molecules such as B7.2, as well as the secretion of inflammatory cytokines such as IL-12 and TNF-α. The results of this study indicate that heat-denatured tumor extracts might elicit protective anti-tumor adaptive immune responses and also raise the possibility that a safe and efficient adjuvant-free tumor vaccine might be developed in conjunction with a dendritic cell-based tumor vaccine.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
http://kmbase.medric.or.kr/Main.aspx?d=KMBASE&m=VIEW&i=0620920080400010130
G704-000088.2008.40.1.008
ISSN:1226-3613
2092-6413
DOI:10.3858/emm.2008.40.1.130